Budoucí P/E společnosti Guided Therapeutics
Jaká je hodnota metriky Budoucí P/E společnosti Guided Therapeutics?
Hodnota metriky Budoucí P/E společnosti Guided Therapeutics, Inc. je N/A
Jaká je definice metriky Budoucí P/E?
Budoucí poměr P/E (Forward price to earnings ratio) vyjadřuje poměr současné ceny a odhadovaného zisku na akcii v následujících dvanácti měsících.
The forward price to earnings ratio is similar to trailing price to earnings ratio but instead of net income uses estimated net earnings over next 12 months. Estimates are typically derived as the mean of those published by a select group of analysts with selection criteria varying. The forward price-to-earnings ratio is a powerful, but limited tool. It allows a quick snapshot of the company’s finances without getting down in the details of an accounting report.
Čemu se věnuje společnost Guided Therapeutics?
Guided Therapeutics, Inc., a medical technology company, focuses on developing medical devices. It focuses on the commercialization of LuViva, a non-invasive cervical cancer detection device that identifies cervical cancers and precancers painlessly, non-invasively, and at the point-of-care by scanning the cervix with light, then analyzing the light reflected and fluorescent light. The company was formerly known as SpectRx, Inc. and changed its name to Guided Therapeutics, Inc. in February 2008. Guided Therapeutics, Inc. was incorporated in 1992 and is based in Norcross, Georgia.